Jack W Coburn

Summary

Country: USA

Publications

  1. ncbi Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4
    Jack W Coburn
    West Los Angeles Veterans Affairs Healthcare Center, Los Angeles, CA 90073, USA
    Am J Kidney Dis 43:877-90. 2004
  2. ncbi The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism
    William G Goodman
    Department of Medicine, Division of Nephrology, Medical Center, UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Am Soc Nephrol 13:1017-24. 2002
  3. ncbi The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism
    Jill S Lindberg
    Ochsner Clinical Research Center, New Orleans, Louisiana 70121, USA
    Kidney Int 63:248-54. 2003
  4. ncbi Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl
    Sharon M Moe
    Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Kidney Int 67:760-71. 2005
  5. ncbi Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study
    Jill S Lindberg
    New Orleans Nephrology Associates, 4228 Houma Boulevard, Metairie, LA 70006, USA
    J Am Soc Nephrol 16:800-7. 2005
  6. ncbi Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis
    Chaim Charytan
    New York Hospital Medical Center of Queens, Flushing, NY 11355, USA
    Am J Kidney Dis 46:58-67. 2005
  7. ncbi Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy
    Kevin J Martin
    Division of Nephrology, Saint Louis University, St. Louis, MO 63110, USA
    Am J Kidney Dis 43:558-65. 2004

Detail Information

Publications7

  1. ncbi Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4
    Jack W Coburn
    West Los Angeles Veterans Affairs Healthcare Center, Los Angeles, CA 90073, USA
    Am J Kidney Dis 43:877-90. 2004
    ..We evaluated doxercalciferol (1alpha-hydroxyvitamin D2) as an alternative therapy in a randomized, double-blinded, placebo-controlled, multicenter trial...
  2. ncbi The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism
    William G Goodman
    Department of Medicine, Division of Nephrology, Medical Center, UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Am Soc Nephrol 13:1017-24. 2002
    ....
  3. ncbi The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism
    Jill S Lindberg
    Ochsner Clinical Research Center, New Orleans, Louisiana 70121, USA
    Kidney Int 63:248-54. 2003
    ..The calcimimetic AMG 073 increases the sensitivity of the parathyroid calcium-sensing receptor to extracellular calcium, thereby reducing PTH secretion. Consequently, AMG 073 may provide a novel therapy for secondary hyperparathyroidism...
  4. ncbi Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl
    Sharon M Moe
    Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Kidney Int 67:760-71. 2005
    ....
  5. ncbi Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study
    Jill S Lindberg
    New Orleans Nephrology Associates, 4228 Houma Boulevard, Metairie, LA 70006, USA
    J Am Soc Nephrol 16:800-7. 2005
    ..Cinacalcet offers a new therapeutic option for controlling secondary hyperparathyroidism in patients with chronic kidney disease on dialysis...
  6. ncbi Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis
    Chaim Charytan
    New York Hospital Medical Center of Queens, Flushing, NY 11355, USA
    Am J Kidney Dis 46:58-67. 2005
    ..This phase 2 study evaluated the effects of the oral calcimimetic cinacalcet hydrochloride in patients with CKD not on dialysis therapy...
  7. ncbi Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy
    Kevin J Martin
    Division of Nephrology, Saint Louis University, St. Louis, MO 63110, USA
    Am J Kidney Dis 43:558-65. 2004